Revenues from Contracts with Customers

12 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues from Contracts with Customers

3. Revenues from Contracts with Customers

The Company disaggregates its revenue into three product portfolios. The primary care portfolio is composed of ZolpiMist and Tuzistra. The pediatric portfolio is composed of Adzenys XR-ODT, Cotempla XR-ODT Poly-Vi-Flor, Tri-Vi-Flor, Karbinal ER and a generic Tussionex. The Consumer Health portfolio is composed of over twenty consumer health products competing in large healthcare categories.

As part of the realization of post-acquisition synergies and product prioritization, the Company has implemented a portfolio rationalization plan whereby it discontinued or divested non-core products including Cefaclor, Flexichamber, Tussionex, Tuzistra XR, and Zolpimist, effectively eliminating the primary care portfolio. These products, collectively, contributed $2.1 million in net revenue and $0.6 million in gross loss during the year ended June 30, 2022 (see Note 8 – Goodwill and Other Intangible Assets).

Revenues by Product Portfolio: Net revenue disaggregated by significant product portfolio for the years ended June 30, 2022 and 2021 were as follows.

	Year Ended
	June 30,
	2022		2021
	(In thousands)
ADHD portfolio	$	42,855	$	10,883
Pediatric portfolio		16,084		12,437
Consumer Health portfolio		35,548		32,954
Other		2,182		9,358
Consolidated revenue	$	96,669	$	65,632

Revenues by Geographic location. The following table reflects our product revenues by geographic location as determined by the billing address of our customers:

	Year Ended
	June 30,
	2022		2021
	(In thousands)
U.S.	$	94,606	$	60,687
International		2,063		4,945
Total net revenue	$	96,669	$	65,632